Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 4—April 2014
CME ACTIVITY - Research

Travel-associated Antimicrobial Drug–Resistant Nontyphoidal Salmonellae, 2004–2009

Russell S. Barlow, Emilio E. DeBessComments to Author , Kevin L. Winthrop, Jodi A. Lapidus, Robert Vega, and Paul R. Cieslak
Author affiliations: Oregon Health Authority, Portland, Oregon USA (R.S. Barlow, E.E. DeBess, P.R. Cieslak); Oregon Health and Science University, Portland (R.S. Barlow, K.L. Winthrop, J.A. Lapidus); Oregon State Public Health Lab, Hillsboro, Oregon, USA (R. Vega)

Main Article

Table 6

Associations of salmonellosis with CIR for 1,571 patients, excluding patients with history of international travel, Oregon, 2004–2009*

Variable No. patients % CIR isolates Odds ratio (95% CI) Adjusted odds ratio (95% CI)
Salmonella serotype
Enteriditis 232 4.3 Referent
Typhimurium 245 22.5 5.6 (2.8–11.5) 6.9 (3.4–14.0)
Heidleberg 147 27.2 6.9 (3.3–14.6) 9.1 (4.3–19.0)
Typhimurium var. Copenhagen 85 52.9 19.7 (8.9–43.4) 26.0 (12.0–56.4)
Newport 66 48.5 16.1 (7.0–36.8) 19.3 (8.7–43.1)
I 4, 5, 12:i:- 77 18.2 3.3 (1.4–8.0) 5.1 (2.2–12.1)
Montevideo 70 4.3 0.7 (0.2–2.8) 1.0 (0.3–3.8)
Saintpaul 43 18.6 5.8 (2.0–16.7) 5.5 (2.0–15.1)
Paratyphi B var. L+ Tartrate+ 45 26.7 6.3 (2.5–16.1) 9.0 (3.5–22.6)
All other
561
8.0
1.6 (0.8–3.3)
1.8 (0.9–3.6)
Case type
Sporadic 1190 18.7 Referent
Outbreak
381
11.0
0.6 (0.4–0.8)
0.5 (0.4–0.8)
Year ( odds of CIR cases/y)
1571 16.8 1.1 (1.0–1.2) 1.1 (1.0–1.2)
Age, y




18–64 817 16.5 Referent
<1 119 18.5 1.1 (0.7–1.9) 1.3 (0.8–2.3)
1–4 204 16.2 0.9 (0.6–1.4) 0.8 (0.5–1.2)
5–17 245 18.8 1.1 (0.8–1.6) 0.9 (0.6–1.4)
>65
186
15.1
0.8 (0.5–1.3)
0.8 (0.5–1.4)
Race
White 1662 16.7 Referent
Not white 151 18.5 1.2 (0.7–1.9) 1.1 (0.7–1.8)

*Multiple logistic regression analysis. CIR, clinically important resistance to >1 of the following: ampicillin, ceftriaxone, ciprofloxacin, gentamicin, or trimethoprim/sulfamethoxazole.clinically important resistance. Boldface indicates statistical significance at p<0.05.

Main Article

Page created: March 18, 2014
Page updated: March 18, 2014
Page reviewed: March 18, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external